Literature DB >> 8348562

Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.

A Eisenthal1, Y Skornick, O Merimsky, R Hirsch, V Zakut, I Ron, S Chaitchik.   

Abstract

In the present study we demonstrate the ability of allogeneic M3 tumor cells to induce an antitumor response against the syngeneic tumor, when injected locally together with syngeneic B16 melanoma cells. The replacement of the allogeneic tumor cells with either syngeneic or allogeneic splenocytes had no effect on the growth of the syngeneic tumor. Systemic administration of both interleukin-2 (IL-2) and IL-6 did not affect the antitumor response induced by allogeneic tumor cells. When mice, previously injected with B16 and M3 cells, were rechallenged subcutaneously with B16 tumor cells at a different anatomical site, an inhibitory effect in some, but not all, experiments was observed. Systemic injections of either IL-2 or IL-6 did not alter the antitumor effects of the allogeneic and syngeneic tumor-cell mixtures. The significance of our results in developing immunotherapy modalities based on active immunization with allogeneic tumor cells and selected cytokines is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348562     DOI: 10.1007/bf01518516

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  40 in total

1.  In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.

Authors:  V Schirrmacher; S Leidig; A Griesbach
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Characterization of IL-2-induced murine cells which exhibit ADCC activity.

Authors:  A Eisenthal; E Shiloni; S A Rosenberg
Journal:  Cell Immunol       Date:  1988-09       Impact factor: 4.868

3.  The selection and characterization of an invasive variant of the B16 melanoma.

Authors:  I R Hart
Journal:  Am J Pathol       Date:  1979-12       Impact factor: 4.307

4.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

5.  Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.

Authors:  I Kawase; K Komuta; M Namba; S Yokota; T Ogura; S Kishimoto
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

6.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

7.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

8.  The in vivo anti-tumor effect of human recombinant interleukin-6.

Authors:  M Kitahara; S Kishimoto; T Hirano; T Kishimoto; M Okada
Journal:  Jpn J Cancer Res       Date:  1990-10

9.  Antitumor activity of recombinant interleukin 6 in mice.

Authors:  J J Mulé; J K McIntosh; D M Jablons; S A Rosenberg
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.